A study employing CRISPR/Cas9 to explore the evolutionary beginnings of some giant viruses finds evidence their large genomes arose from gene duplications.
Immune defense genes in bacteria and archaea can identify viral proteins, a study finds, revealing similarities between the immune systems of prokaryotic and eukaryotic organisms.
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
This month marks ten years since CRISPR-Cas9 was repurposed as a gene editing system, so we’re looking back at what has been accomplished in a decade of CRISPR editing.
A first-of-its-kind gene therapy dramatically reduced misfolded protein levels in some clinical trial participants for up to six months and reduced levels in all participants for up to a year.
The US Patent and Trademark Office has once again decided that the institute has priority over the University of California and collaborators regarding intellectual property rights for CRISPR-Cas9 gene editing in eukaryotes. But the fight over the technique isn’t over.